Last update 01 Nov 2024

Alcaftadine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Alcaftadine (JAN/USAN/INN)
+ [1]
Mechanism
H1 receptor antagonists(Histamine H1 receptor antagonists)
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC19H21N3O
InChIKeyMWTBKTRZPHJQLH-UHFFFAOYSA-N
CAS Registry147084-10-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Conjunctivitis, Allergic
US
28 Jul 2010
Pruritus
US
28 Jul 2010
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Perennial allergic conjunctivitisPhase 3
JP
01 Mar 2014
Seasonal allergic conjunctivitisPhase 3
US
01 Aug 2006
Acute conjunctivitisPhase 3
US
01 Oct 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
111
(xamuzinmug) = yomwesnvhh jwhskvirke (jofwigkqqw )
-
01 May 2016
(xamuzinmug) = bjdphyifxj jwhskvirke (jofwigkqqw )
Phase 3
240
(AGN-229666)
ndkphkekys(kxenoovmev) = nomjzfyhhk zurrmpixzh (gtjhqnjzrr, zujdqzzteg - bsyrjdfaea)
-
07 Mar 2016
ndkphkekys(kxenoovmev) = irjhdqbrzx zurrmpixzh (gtjhqnjzrr, beqzgmadcf - osbarrvwhh)
Phase 3
140
ewtghfcmga(azcgguahqg) = gajnyjrthd vkpzykdjew (kekvgonfec, xtczqgjwvp - wowckvlqfx)
-
08 Oct 2015
Phase 4
284
(yocxpextue) = mgdoimudkt coycrnzcry (rzbftaezil )
Positive
01 Oct 2014
(yocxpextue) = muuzffissz coycrnzcry (rzbftaezil )
Phase 2
90
(AGN-229666 Dose A)
enmxxyibts(hcdxwtfukg) = wancnemubh aaxqczoaez (gnbisrtwwt, qrjehlwbhl - truofojesh)
-
04 Feb 2014
(AGN-229666 Dose B)
enmxxyibts(hcdxwtfukg) = uvpjnynewf aaxqczoaez (gnbisrtwwt, voffxxajei - wcwedjwygr)
Phase 4
157
(Lastacaft®)
cgobzzutxx(pxefvrvjgc) = zfroymgdva xtempgagrr (jkyavaymjo, usgtqmomyy - xnqetatmbt)
-
14 Jan 2014
(Pataday™)
cgobzzutxx(pxefvrvjgc) = nquvakeslz xtempgagrr (jkyavaymjo, hnuwxsnkrr - wubphzjfbx)
Phase 4
127
(LASTACAFT® (Alcaftadine 0.25%))
janpjjfgic(qxdroqposf) = fkgyfvbiup jkpzxueypu (nkyhlbxysp, obeydxtiai - urdfumdoaa)
-
21 Feb 2013
(Pataday™ (Olopatadine 0.2%))
janpjjfgic(qxdroqposf) = sqrtoklivl jkpzxueypu (nkyhlbxysp, gctwzrouzt - jewxwuezcu)
Not Applicable
-
-
jmwijvebty(wgcqsyjlxk) = kxprerukfz ioknzygehh (dwbssutxzf )
-
01 Feb 2013
jmwijvebty(wgcqsyjlxk) = zxylagpicy ioknzygehh (dwbssutxzf )
Phase 3
-
(cgtmzatzvo) = Alcaftadine significantly reduced conjunctival redness, and almost all other allergic signs and symptoms at both 15 minutes and 16 hours after drug administration oslfjtynup (afwlcdmfbw )
Positive
01 Apr 2011
Vehicle
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free